Search - tctmd.com

Displaying 821 - 840 of 1037

Sort: Relevancy | Date

Valve Leaflet Thrombosis: Treat It or Leave It Be?

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

June 19, 2017

Mitral Valve Repair Technologies Inch Forward, but Question of Combination Therapy Looms

News Conference News TVT 2017

Mitral Valve Repair Technologies Inch Forward, but Question of Combination Therapy Looms

June 15, 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

June 12, 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

May 17, 2017

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

News Conference News EuroPCR 2017

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

May 17, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

News Conference News SCAI 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

May 15, 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

May 12, 2017

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

News Conference News

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

April 07, 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

March 27, 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

March 23, 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

March 18, 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.